Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethyl Benzoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.67 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.64 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.64 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.64 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.62 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Benzoate SCHEMBL27399492 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL10731730 | 0.98 | LMNA (0.66) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL11047078 | 0.98 | LMNA (0.66) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL10894118 | 0.98 | LMNA (0.66) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL25388294 | 0.98 | LMNA (0.70) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL55674 | 0.98 | LMNA (0.70) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL2762273 | 0.98 | LMNA (0.70) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL29554608 | 0.96 | LMNA (0.68) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL28365249 | 0.96 | LMNA (0.68) | LMNASMN1; SMN2RAB9ANPC1GAA | |
| Ethyl Benzoate SCHEMBL1404143 | 0.96 | LMNA (0.68) | LMNASMN1; SMN2RAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666770-A | Chiral tridentate anionic ligand containing oxazoline fragment and synthesis method and application thereof | 武汉理工大学 | 2024-09-20 | — | — | CN | claimed |
| CN-111362957-B | Preparation method of icotinib key intermediate | 上海百利佳生医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-111909163-B | Quinolamine compound with IDO1 inhibition function and preparation method thereof | 南开大学 | 2022-02-01 | — | — | CN | claimed |
| CN-109678707-A | A kind of deuterium-labeled D3The synthetic method of salbutamol | 东莞暨南大学研究院 | 2019-04-26 | — | — | CN | claimed |
| CN-109096136-A | Tarceva midbody compound and its refining methd | 山东金城医药化工有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-104725327-B | A kind of environment-friendly preparation method of erlotinib Hydrochloride | 山东大学 | 2017-08-25 | — | — | CN | claimed |
| CN-104725327-A | Environment-friendly method for preparing high-yield erlotinib hydrochloride | UNIV SHANDONG | 2015-06-24 | — | — | CN | claimed |
| CN-103459377-A | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators | LUPIN LTD | 2013-12-18 | — | — | CN | claimed |
| US-20260125740-A1 | PRIMERS FOR IMMUNE REPERTOIRE PROFILING | BECTON DICKINSON CO (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4679088-A2 | NON-SEQUENCING PCR-BASED METHOD FOR DETECTION OF ANTIBODY-CONJUGATED OLIGONUCLEOTIDES | Becton, Dickinson and Company (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4399327-B1 | NON-SEQUENCING PCR-BASED METHOD FOR DETECTION OF ANTIBODY-CONJUGATED OLIGONUCLEOTIDES | BECTON DICKINSON CO (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12378594-B2 | Primers for immune repertoire profiling | BECTON, DICKINSON AND COMPANY (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250129405-A1 | NON-SEQUENCING PCR-BASED METHOD FOR DETECTION OF ANTIBODY-CONJUGATED OLIGONUCLEOTIDES | BECTON, DICKINSON AND COMPANY | 2025-04-24 | — | — | US | disclosed |
| CN-115151304-B | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-4533707-A | POLYMERIZATION WITH COORDINATION CATALYST | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-08-06 | — | — | US | disclosed |
| US-4465782-A | Supported transition metal composition | Imperial Chemistry Industries PLC (GB) | 1984-08-14 | — | — | US | disclosed |
| US-4465783-A | REDUCTION IN PARTICLE SIZE, THEN SPRAY DRYING OF TRANSITION METAL COMPOUND IN (HAL-)HYDROCARBON | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-14 | — | — | US | disclosed |
| EP-0072129-A2 | Supported transition metal composition | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-02-16 | — | — | EP | disclosed |
| EP-0072128-A2 | Spraying solid | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-02-16 | — | — | EP | disclosed |
| US-4076924-A | CATALYST COMPRISING A TITANIUM COMPONENT AND A GROUP I TO III ORGANO-METAL COMPOUND | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125740-A1 | PRIMERS FOR IMMUNE REPERTOIRE PROFILING | CD74, BCR, MYD88 | GAA 4733/4885CA2 4247/4885ESR1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.